Shopping Cart 0
Cart Subtotal
AED 0

Helix BioPharma Corp (HBP) - Financial and Strategic SWOT Analysis Review

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
AED 459

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
AED 918

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
AED 1376
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Helix BioPharma Corp (HBP)-Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description-A detailed description of the company's operations and business divisions.

- Corporate strategy-Analyst's summarization of the company's business strategy.

- SWOT Analysis-A detailed analysis of the company's strengths, weakness, opportunities and threats.

- Company history-Progression of key events associated with the company.

- Major products and services-A list of major products, services and brands of the company.

- Key competitors-A list of key competitors to the company.

- Key employees-A list of the key executives of the company.

- Executive biographies-A brief summary of the executives' employment history.

- Key operational heads-A list of personnel heading key departments/functions.

- Important locations and subsidiaries-A list and contact details of key locations and subsidiaries of the company.

- Key manufacturing facilities-A list of key manufacturing facilities of the company.

- Detailed financial ratios for the past five years-The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

- Interim ratios for the last five interim periods-The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Helix BioPharma Corp (Helix) is a biopharmaceutical company with a focus in the field of cancer therapy. It develops drug candidates for the prevention and treatment of cancer. It develops drugs based on its proprietary technologies. DOS47, the company's proprietary broad anti-cancer therapeutic platform has yielded two new drug product candidates, V-DOS47 and L-DOS47. V-DOS47 uses the company's proprietary DOS47 technology conjugated to VEGFR target wide range of cancers and L-DOS47 is designed to treat inoperable, locally advanced, recurrent or metastatic non-small cell lung cancer (NSCLC). It also continues to actively pursue additional novel antibody based technologies for cell-based therapies. Helix is headquartered in Aurora, Ontario, Canada.

Helix BioPharma Corp Key Recent Developments

Jun 12,2018: Helix BioPharma Reports Fiscal Third Quarter 2018 Financial Results

Mar 22,2018: Helix BioPharma Welcomes Drs. Daniel Von Hoff, Kazimierz Roszkowski-Sliz and Robert Gillies to Its Scientific and Strategic Advisory Board

Mar 20,2018: Helix BioPharma Announces Fiscal Second Quarter 2018 Results

Dec 13,2017: Helix BioPharma Announces Fiscal First Quarter 2018 Results

Dec 01,2017: Helix BioPharma Announces Management Change

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

- The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Section 1-About the Company 6

Helix BioPharma Corp-Key Facts 6

Helix BioPharma Corp-Key Employees 7

Helix BioPharma Corp-Key Employee Biographies 8

Helix BioPharma Corp-Major Products and Services 9

Helix BioPharma Corp-History 10

Helix BioPharma Corp-Company Statement 12

Helix BioPharma Corp-Locations And Subsidiaries 13

Head Office 13

Other Locations & Subsidiaries 13

Section 2-Company Analysis 14

Company Overview 14

Helix BioPharma Corp-Business Description 15

Helix BioPharma Corp-Corporate Strategy 16

Helix BioPharma Corp-SWOT Analysis 17

SWOT Analysis-Overview 17

Helix BioPharma Corp-Strengths 17

Helix BioPharma Corp-Weaknesses 18

Helix BioPharma Corp-Opportunities 19

Helix BioPharma Corp-Threats 20

Helix BioPharma Corp-Key Competitors 21

Section 3-Company Financial Ratios 22

Financial Ratios-Capital Market Ratios 22

Financial Ratios-Annual Ratios 23

Performance Chart 24

Financial Performance 24

Financial Ratios-Interim Ratios 25

Financial Ratios-Ratio Charts 26

Section 4-Company's Lifesciences Financial Deals and Alliances 27

Helix BioPharma Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 27

Helix BioPharma Corp, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 28

Helix BioPharma Corp, Recent Deals Summary 29

Section 5-Company's Recent Developments 30

Mar 22, 2018: Helix BioPharma Welcomes Drs. Daniel Von Hoff, Kazimierz Roszkowski-Sliz and Robert Gillies to Its Scientific and Strategic Advisory Board 30

Mar 20, 2018: Helix BioPharma Announces Fiscal Second Quarter 2018 Results 31

Dec 13, 2017: Helix BioPharma Announces Fiscal First Quarter 2018 Results 33

Dec 01, 2017: Helix BioPharma Announces Management Change 34

Oct 27, 2017: Helix BioPharma Announces Fiscal 2017 Year-End Results and Provides Research and Development Program Update 35

Jul 17, 2017: Helix BioPharma Director Resigns 37

Jul 17, 2017: Helix BioPharma Director Resigns 38

Jun 13, 2017: Helix BioPharma Announces Fiscal Third Quarter 2017 Results 39

Mar 17, 2017: Helix BioPharma Announces Fiscal Second Quarter 2017 Results 41

Mar 07, 2017: Helix BioPharma Announces Strategic Management Changes 42

Section 6-Appendix 43

Methodology 43

Ratio Definitions 43

About GlobalData 47

Contact Us 47

Disclaimer 47


List Of Figure

List of Figures

Helix BioPharma Corp, Performance Chart (2013-2017) 24

Helix BioPharma Corp, Ratio Charts 26

Helix BioPharma Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 27

Helix BioPharma Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 28


List Of Table

List of Tables

Helix BioPharma Corp, Key Facts 6

Helix BioPharma Corp, Key Employees 7

Helix BioPharma Corp, Key Employee Biographies 8

Helix BioPharma Corp, Major Products and Services 9

Helix BioPharma Corp, History 10

Helix BioPharma Corp, Subsidiaries 13

Helix BioPharma Corp, Key Competitors 21

Helix BioPharma Corp, Ratios based on current share price 22

Helix BioPharma Corp, Annual Ratios 23

Helix BioPharma Corp, Interim Ratios 25

Helix BioPharma Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 27

Helix BioPharma Corp, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 28

Helix BioPharma Corp, Recent Deals Summary 29

Currency Codes 43

Capital Market Ratios 43

Equity Ratios 44

Profitability Ratios 44

Cost Ratios 45

Liquidity Ratios 45

Leverage Ratios 46

Efficiency Ratios 46

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

Helix BioPharma Corp, SWOT analysis, SWOT, Strengths, Weaknesses, Opportunities, Threats, Corporate Strategy, Key Ratios, Share Data, Performance, Financial Performance, Overview, Business Description, Major Product, Brands, History,Key Employees, Key Operational Heads, Strategy, Key Competitors, Company Statement, Capital Market Ratios, Financial Ratios, Annual Ratios, Interim Ratios, Ratio Charts


Companies

Photocure Inc

Nanovir LLC

Merck & Co Inc

GlaxoSmithKline Inc

Foamix Pharmaceuticals Ltd

Bristol-Myers Squibb Co

Helix BioPharma Corp (HBP)-Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description-A detailed description of the company's operations and business divisions.

- Corporate strategy-Analyst's summarization of the company's business strategy.

- SWOT Analysis-A detailed analysis of the company's strengths, weakness, opportunities and threats.

- Company history-Progression of key events associated with the company.

- Major products and services-A list of major products, services and brands of the company.

- Key competitors-A list of key competitors to the company.

- Key employees-A list of the key executives of the company.

- Executive biographies-A brief summary of the executives' employment history.

- Key operational heads-A list of personnel heading key departments/functions.

- Important locations and subsidiaries-A list and contact details of key locations and subsidiaries of the company.

- Key manufacturing facilities-A list of key manufacturing facilities of the company.

- Detailed financial ratios for the past five years-The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

- Interim ratios for the last five interim periods-The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Helix BioPharma Corp (Helix) is a biopharmaceutical company with a focus in the field of cancer therapy. It develops drug candidates for the prevention and treatment of cancer. It develops drugs based on its proprietary technologies. DOS47, the company's proprietary broad anti-cancer therapeutic platform has yielded two new drug product candidates, V-DOS47 and L-DOS47. V-DOS47 uses the company's proprietary DOS47 technology conjugated to VEGFR target wide range of cancers and L-DOS47 is designed to treat inoperable, locally advanced, recurrent or metastatic non-small cell lung cancer (NSCLC). It also continues to actively pursue additional novel antibody based technologies for cell-based therapies. Helix is headquartered in Aurora, Ontario, Canada.

Helix BioPharma Corp Key Recent Developments

Jun 12,2018: Helix BioPharma Reports Fiscal Third Quarter 2018 Financial Results

Mar 22,2018: Helix BioPharma Welcomes Drs. Daniel Von Hoff, Kazimierz Roszkowski-Sliz and Robert Gillies to Its Scientific and Strategic Advisory Board

Mar 20,2018: Helix BioPharma Announces Fiscal Second Quarter 2018 Results

Dec 13,2017: Helix BioPharma Announces Fiscal First Quarter 2018 Results

Dec 01,2017: Helix BioPharma Announces Management Change

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

- The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Section 1-About the Company 6

Helix BioPharma Corp-Key Facts 6

Helix BioPharma Corp-Key Employees 7

Helix BioPharma Corp-Key Employee Biographies 8

Helix BioPharma Corp-Major Products and Services 9

Helix BioPharma Corp-History 10

Helix BioPharma Corp-Company Statement 12

Helix BioPharma Corp-Locations And Subsidiaries 13

Head Office 13

Other Locations & Subsidiaries 13

Section 2-Company Analysis 14

Company Overview 14

Helix BioPharma Corp-Business Description 15

Helix BioPharma Corp-Corporate Strategy 16

Helix BioPharma Corp-SWOT Analysis 17

SWOT Analysis-Overview 17

Helix BioPharma Corp-Strengths 17

Helix BioPharma Corp-Weaknesses 18

Helix BioPharma Corp-Opportunities 19

Helix BioPharma Corp-Threats 20

Helix BioPharma Corp-Key Competitors 21

Section 3-Company Financial Ratios 22

Financial Ratios-Capital Market Ratios 22

Financial Ratios-Annual Ratios 23

Performance Chart 24

Financial Performance 24

Financial Ratios-Interim Ratios 25

Financial Ratios-Ratio Charts 26

Section 4-Company's Lifesciences Financial Deals and Alliances 27

Helix BioPharma Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 27

Helix BioPharma Corp, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 28

Helix BioPharma Corp, Recent Deals Summary 29

Section 5-Company's Recent Developments 30

Mar 22, 2018: Helix BioPharma Welcomes Drs. Daniel Von Hoff, Kazimierz Roszkowski-Sliz and Robert Gillies to Its Scientific and Strategic Advisory Board 30

Mar 20, 2018: Helix BioPharma Announces Fiscal Second Quarter 2018 Results 31

Dec 13, 2017: Helix BioPharma Announces Fiscal First Quarter 2018 Results 33

Dec 01, 2017: Helix BioPharma Announces Management Change 34

Oct 27, 2017: Helix BioPharma Announces Fiscal 2017 Year-End Results and Provides Research and Development Program Update 35

Jul 17, 2017: Helix BioPharma Director Resigns 37

Jul 17, 2017: Helix BioPharma Director Resigns 38

Jun 13, 2017: Helix BioPharma Announces Fiscal Third Quarter 2017 Results 39

Mar 17, 2017: Helix BioPharma Announces Fiscal Second Quarter 2017 Results 41

Mar 07, 2017: Helix BioPharma Announces Strategic Management Changes 42

Section 6-Appendix 43

Methodology 43

Ratio Definitions 43

About GlobalData 47

Contact Us 47

Disclaimer 47


List Of Figure

List of Figures

Helix BioPharma Corp, Performance Chart (2013-2017) 24

Helix BioPharma Corp, Ratio Charts 26

Helix BioPharma Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 27

Helix BioPharma Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 28


List Of Table

List of Tables

Helix BioPharma Corp, Key Facts 6

Helix BioPharma Corp, Key Employees 7

Helix BioPharma Corp, Key Employee Biographies 8

Helix BioPharma Corp, Major Products and Services 9

Helix BioPharma Corp, History 10

Helix BioPharma Corp, Subsidiaries 13

Helix BioPharma Corp, Key Competitors 21

Helix BioPharma Corp, Ratios based on current share price 22

Helix BioPharma Corp, Annual Ratios 23

Helix BioPharma Corp, Interim Ratios 25

Helix BioPharma Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 27

Helix BioPharma Corp, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 28

Helix BioPharma Corp, Recent Deals Summary 29

Currency Codes 43

Capital Market Ratios 43

Equity Ratios 44

Profitability Ratios 44

Cost Ratios 45

Liquidity Ratios 45

Leverage Ratios 46

Efficiency Ratios 46

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products

Helix BioPharma Corp, SWOT analysis, SWOT, Strengths, Weaknesses, Opportunities, Threats, Corporate Strategy, Key Ratios, Share Data, Performance, Financial Performance, Overview, Business Description, Major Product, Brands, History,Key Employees, Key Operational Heads, Strategy, Key Competitors, Company Statement, Capital Market Ratios, Financial Ratios, Annual Ratios, Interim Ratios, Ratio Charts


Companies

Photocure Inc

Nanovir LLC

Merck & Co Inc

GlaxoSmithKline Inc

Foamix Pharmaceuticals Ltd

Bristol-Myers Squibb Co

chat_bubbleLet's Chat